» Articles » PMID: 37033223

Identification of Shared Genetic Architecture Between Non-alcoholic Fatty Liver Disease and Type 2 Diabetes: A Genome-wide Analysis

Overview
Specialty Endocrinology
Date 2023 Apr 10
PMID 37033223
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The incidence of complications of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) has been increasing.

Method: In order to identify the shared genetic architecture of the two disease phenotypes of NAFLD and T2D, a European population-based GWAS summary and a cross-trait meta-analysis was used to identify significant shared genes for NAFLD and T2D. The enrichment of shared genes was then determined through the use of functional enrichment analysis to investigate the relationship between genes and phenotypes. Additionally, differential gene expression analysis was performed, significant differentially expressed genes in NAFLD and T2D were identified, genes that overlapped between those that were differentially expressed and cross-trait results were reported, and enrichment analysis was performed on the core genes that had been obtained in this way. Finally, the application of a bidirectional Mendelian randomization (MR) approach determined the causal link between NAFLD and T2D.

Result: A total of 115 genes were discovered to be shared between NAFLD and T2D in the GWAS analysis. The enrichment analysis of these genes showed that some were involved in the processes such as the decomposition and metabolism of lipids, phospholipids, and glycerophospholipids. Additionally, through the use of differential gene expression analysis, 15 core genes were confirmed to be linked to both T2D and NAFLD. They were correlated with carcinoma cells and inflammation. Furthermore, the bidirectional MR identified a positive causal relationship between NAFLD and T2D.

Conclusion: Our study determined the genetic structure shared between NAFLD and T2D, offering a new reference for the genetic pathogenesis and mechanism of NAFLD and T2D comorbidities.

Citing Articles

Diagnosis and Staging of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Biomarker-Directed Aptamer Panels.

Kjaer M, Jorgensen A, Fjelstrup S, Dupont D, Bus C, Eriksen P Biomolecules. 2025; 15(2).

PMID: 40001558 PMC: 11852711. DOI: 10.3390/biom15020255.


Steatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes.

Putri R, Casswall T, Danielsson P, Marcus C, Hagman E Diabetes Care. 2024; 47(12):2196-2204.

PMID: 39373987 PMC: 11655408. DOI: 10.2337/dc24-1236.


Association between diabetes mellitus and primary biliary cholangitis: a two-sample Mendelian randomization study.

Lv D, Wang H, Leng Y, Chen S, Sun H, Meng X Front Endocrinol (Lausanne). 2024; 15:1362584.

PMID: 38774228 PMC: 11106416. DOI: 10.3389/fendo.2024.1362584.


Associations between type 2 diabetes mellitus and chronic liver diseases: evidence from a Mendelian randomization study in Europeans and East Asians.

Zhao Y, Li D, Shi H, Liu W, Qiao J, Wang S Front Endocrinol (Lausanne). 2024; 15:1338465.

PMID: 38495785 PMC: 10941029. DOI: 10.3389/fendo.2024.1338465.

References
1.
Anstee Q, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D . Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J Hepatol. 2020; 73(3):505-515. DOI: 10.1016/j.jhep.2020.04.003. View

2.
Pinero F, Pages J, Marciano S, Fernandez N, Silva J, Anders M . Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol. 2018; 10(1):41-50. PMC: 5787683. DOI: 10.4254/wjh.v10.i1.41. View

3.
Mounier N, Kutalik Z . Bias correction for inverse variance weighting Mendelian randomization. Genet Epidemiol. 2023; 47(4):314-331. DOI: 10.1002/gepi.22522. View

4.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M . Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50(8):1844-50. DOI: 10.2337/diabetes.50.8.1844. View

5.
Wang Z, Chen J, Wang S, Sun Z, Lei Z, Zhang H . RGS6 suppresses TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4. Cell Death Dis. 2022; 13(7):656. PMC: 9334288. DOI: 10.1038/s41419-022-05093-0. View